Studies suggest that the majority of pediatric patients with cancer and COVID-19 experience mild disease — rather than severe disease — as a result of infection with the novel virus.
There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.
Phase 3 clinical trial of combination shows survival and quality-of-life benefits vs the standard of care, sorafenib, leading to the regimen’s expedited regulatory approval.
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
A trial in phase 2 metastatic prostate cancer shows that some patients likely to benefit from ipilimumab treatment, even with low number of tumor mutations.
Researchers find a type of E.coli often found in the normal gut microbiome secretes a genotoxic substance, which leaves a mutational fingerprint linked to some cases of colorectal cancer.
New study compares published data from various treatment regimens for multiple myeloma, scoring them on efficacy, cost, and adverse effects.
The median total cost of hospitalization resulting from CAR-T treatment was found to be $380,052, with a median direct cost of $262,981.
Researchers have engineered CAR-T cells to express a peptide from scorpion venom to help them home to glioma cells.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
